Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $136.00. Evan Seigerman has given his ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

German pharma and technology giant Merck has announced a €5 million (£4.2m) investment in Scotland that will create further jobs at its diagnostics and blood typing facility in Livingston.

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price target to $123.00. Terence Flynn’s rating is based on several ...

Merck & Co. Inc.'s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to charges stemming from deals with partners Curon ...